Dyax, an integrated biopharmaceutical company, has decided to discontinue its Phase 2 trial of ecallantide for acute treatment of angiotensin converting enzyme (ACE) inhibitor-induced angioedema, based on the data from an interim analysis.

The double-blind, placebo-controlled study was planned to evaluate the efficacy and safety of ecallantide (10, 30, or 60mg subcutaneous doses) compared to the placebo.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The proportion of patients meeting a set of criteria indicating eligibility for discharge from the emergency department within six hours after study drug administration was the primary endpoint of the randomised, dose-ranging tests.

Dyax president and chief executive officer Gustav Christensen said that the company would continue to actively investigate novel therapeutic approaches for angioedema disorders, including next generation therapies and testing.

"These results, while unanticipated, provide us with further evidence and understanding of the biology of angioedema, supporting our efforts to address these disorders and to remain at the forefront of therapeutic innovation."

"These results, while unanticipated, provide us with further evidence and understanding of the biology of angioedema, supporting our efforts to address these disorders and to remain at the forefront of therapeutic innovation," Christensen added.

See Also:

An independent Data Safety Monitoring Board, which reviewed blinded safety data for the first 25% of patients in the trial, did not spot any safety concerns or recommended any changes to the conduct of the study.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Although the data from the first 72 patients treated in the trial suggested a trend favouring a treatment with ecallantide over a placebo, it was not statistically significant.

The study was determined to be poorly powered to detect a statistically significant difference between ecallantide and the placebo, as the observed response rate to the placebo was substantially higher than originally anticipated; in addition, the enrolled population does not appear to reproduce the high morbidity described in previous medical literature.

Dyax chief medical officer Burt Adelman added: "These results have no bearing on the use of Kalbitor (ecallantide) to treat patients during an acute attack of HAE."